Biotechnology · San Diego, California, United States
$5.91
-1.66% (-$0.10)2026-07-10
Smart-Money SignalNeutral · 53/100— Insider open-market flow is flat over 90 days
Revenue$0
Net Income-$6.9M
EPS$-9.64
Market Cap$66.1M
Price Performance
Historical data including institutional events
Company Profile
K
Kristin Yarema
CEO & Executive Director
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
ImageneBio, Inc. is headquartered in San Diego, California.
